Abstract
All state funded healthcare providers have to ensure that they provide value for money and avoid wasting money on less cost-effective interventions. The National Health Service (NHS) is the largest public-funded healthcare service in the world, and as a consequence has developed an international reputation for Healthcare Technology Assessment (HTA). The challenge to provide safe, effective drugs on a budget has underpinned the development of cost-saving measures including cost-utility analysis, providing an assessment of cost-effectiveness that can successfully compare the societal value of disparate interventions and their effect on disease states.
In this chapter, we discuss the evolution of HTA in the UK and how financial pressures have driven a review of how we pay for drugs. Value Based Pricing (VBP), and latterly Value Based Assessment (VBA), have been proposed as novel approaches to updating drug pricing in the UK. These schemes aim to ascertain the perceived value of a drug with reference to societal utility and reimburse drug companies accordingly, with the aim of balancing affordability and innovation. We address VBP methodology, cost-effectiveness thresholds, pricing, the need for evidence and VBP experience beyond the UK. Rejuvenating our approach to drug pricing and replacing an outdated system is an invaluable opportunity, yet care must be taken not to inadvertently limit access to cost-effective drugs for those who need them.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ABPI (2011) Value-based pricing: key recommendations from ABPI. ABPI. http://www.abpi.org.uk/media-centre/newsreleases/2011/Pages/140311.aspx. Accessed 24 June 2014
Bennie M, Dear J, Hems S et al (2011) An investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland’s Health Service. Br J Clin Pharmacol 71:283–288
Boseley S (2010) NICE to lose powers to decide on new drugs. The Guardian, 29 Oct. http://www.guardian.co.uk/politics/2010/oct/29/nice-to-lose-new-drug-power. Accessed 24 June 2014
Brazier J, Longworth L (2011). NICE DSU technical support document 8: an introduction to the measurement and valuation of health for NICE submission. NICE Decision Support Unit. http://www.nicedsu.org.uk/Utilities-TSD-series(2391676).htm. Accessed 24 June 2014
Brazier J, Rowen D (2011). NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values. NICE Decision Support Unit. http://www.nicedsu.org.uk/Utilities-TSD-series(2391676).htm. Accessed 24 June 2014
Breckenridge A, Walley T (2008) Risk sharing and payment by results. Clin Pharmacol Ther 83:666–667
Cairns J (2006) Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy 76:134–143
Claxton K (2007) OFT, VBP: QED? Health Econ 16:545–558
Claxton K, Briggs A, Buxton MJ et al (2008) Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336:251
Collier J (2007) The pharmaceutical price regulation scheme. BMJ 334:435–436
Collins M, Latimer N (2013) NICE’s end of life decision making scheme: impact on population health. BMJ 346:f1363
Cullen A (2011) Boehringer, Lilly won’t introduce Trajenta in Germany on pricing. Bloomberg. http://www.bloomberg.com/news/2011-09-02/boehringer-lilly-won-t-introduce-trajenta-in-germany-on-pricing.html. Accessed 24 June 2014
Darrow JJ, Avorn J, Kesselheim AS (2014) New FDA breakthrough-drug category—implications for patients. N Engl J Med 370:1252–1258
Davis K, Stremikis K, Squires D et al (2014) Mirror, mirror on the wall: how the performance of the US healthcare system compares internationally. The Commonwealth Fund. http://www.commonwealthfund.org/publications/fund-reports/2014/jun/mirror-mirror. Accessed 24 June 2014
Department for Business, Innovation and Skills (2014) Innovations report: innovation, research and skills. Department for Business, Innovation and Skills. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/293635/bis-14-p188-innovation-report-2014-revised.pdf. Accessed 24 June 2014
Dixon S, Tsuchiya A, Bazier J, et al (2011) Proceed with caution: an economic perspective on the UK’s value based pricing proposals. The University of Sheffield. HEDS discussion paper (Unpublished). http://eprints.whiterose.ac.uk/42942/. Accessed 24 June 2014
DoH (2010a) Equality and excellence—liberating the NHS. Department of Health. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213823/dh_117794.pdf. Accessed 23 June 2014
DoH (2010b) A new value based approach for the pricing of branded medicines—a consultation. Department of Health. http://webarchive.nationalarchives.gov.uk/20130107105354/ http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_122793.pdf. Accessed 24 May 2014
DoH (2012) The pharmaceutical price regulation scheme: eleventh report to parliament. Department of Health. https://www.gov.uk/government/publications/pharmaceutical-price-regulation-scheme-11th-report-to-parliament. Accessed 24 June 2014
DoH (2013) NHS Constitution. Department of Health. https://www.gov.uk/government/publications/the-nhs-constitution-for-england. Accessed 23 June 2014
Dolan P, Tsuchiya A (2006) The elicitation of distributional judgements in the context of economic evaluation. In: Jones A (ed) Companion to health economics, 1st edn. Elgar, Northampton
Eichler HG, Oye K, Baird LG et al (2012) Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 3:426–437
EMA (2014a) Orphan designation. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000029.jsp. Accessed 24 June 2014
EMA (2014b) Pilot project on adaptive licensing. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/03/news_detail_002046.jsp&mid=WC0b01ac058004d5c1. Accessed 24 June 2014
European Commission (2012). Cost-containment policies in public pharmaceutical spending in the EU. Directorate-General for Economic and Financial Affairs, European Commission. http://bookshop.europa.eu/en/cost-containment-policies-in-public-pharmaceutical-spending-in-the-eu-pbKCAI12461/. Accessed 24 June 2014
FDA (2011). Proposal to withdraw approval for the breast cancer indication for Avastin (bevacizumab): decision of the Commissioner. Department of Health and Human Services, Food and Drug Administration. http://www.fda.gov/downloads/NewsEvents/Newsroom/UCM280546.pdf. Accessed 24 June 2014
Fernando S, Moss A (2013) UK value-based pricing will struggle to materialise as year-end deadline approaches. The FT. http://www.ft.com/cms/s/2/db268c82-8be8-11e2-b001-00144feabdc0.html#axzz30wzZCRUu. Accessed 23 June 2014
Ford JA, Waugh N, Sharma P et al (2012) NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium. BMJ Open 2:e000671
Garber AM, McClellan MB (2007) Satisfaction guaranteed—‘payment by results’ for biologic agents. N Engl J Med 357:1575–1577
Green J, Wintfeld N (1993) How accurate are hospital discharge data for evaluating effectiveness of care? Med Care 31:719–731
HM Treasury (2012) Public expenditure: statistical analyses 2012. HM Treasury. https://www.gov.uk/government/publications/public-expenditure-statistical-analyses-2012. Accessed 24 June 2014
Hutton J, Trueman P, Henshall C (2007) Coverage with evidence development: an examination of conceptual and policy issues. Int J Technol Assess Health Care 23:425–435
Kearney J, Pearce S, Burgin N et al (2013) The pharmaceutical giants’ letter: in full. The Telegraph, 14 Nov 2013. http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/10449540/The-pharmaceutical-giants-letter-in-full.html. Accessed 24 June 2014
Leopold C, Vogler S, Mantel-Teeuwisse A et al (2012) Differences in external price referencing in Europe: a descriptive overview. Health Policy 104:50–60
Linley WG, Hughes DA (2013) Societal views on NICE, Cancer Drugs Fund and value based pricing criteria for prioritizing medicines: a cross sectional survey of 4118 adults in Great Britain. Health Econ 22:948–964
Lopez-Gonzalez E, Herdeiro MT, Figueiras A (2009) Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 32:19–31
Martin S, Rice N, Smith PC (2007) The link between health care spending and health outcomes: evidence from English programme budgeting data. The Health Foundation. http://www.health.org.uk/publications/programme-budgeting-report/. Accessed 24 June 2014
Morgan SG, Bassett KL, Wright JM et al (2005) “Breakthrough” drugs and growth in expenditure on prescription drugs in Canada. BMJ 331:815
NHS Information Centre (2013) Prescriptions dispensed in the community: England, statistics for 2002–2012. NHS Information centre. http://www.hscic.gov.uk/catalogue/PUB06941. Accessed 24 June 2014
NICE (2002) Health Technology Assessment No 32—Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE. http://guidance.nice.org.uk/TA32/Guidance/pdf/English. Accessed 24 June 2014
NICE (2014a) List of technologies with approved patient access schemes, recommended by NICE for use in the NHS. NICE. http://www.nice.org.uk/aboutnice/howwework/paslu/ListOfPatientAccessSchemesApprovedAsPartOfANICEAppraisal.jsp. Accessed 24 June 2014
NICE (2014b) Methods of technology appraisal consultation: burden of illness briefing paper. NICE Decision support unit. http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp?domedia=1&mid=FE327531-EDE9-5747-133DB5A5F835A980. Accessed 24 June 2014
OECD (2013) OECD: health statistics 2013. OECD. http://www.oecd.org/els/health-systems/oecdhealthdata2013-frequentlyrequesteddata.htm. Accessed 24 June 2014
OFT (2007) The pharmaceutical price regulation scheme: an OFT market study. Office of Fair Trading. http://webarchive.nationalarchives.gov.uk/20140402142426/ http://www.oft.gov.uk/OFTwork/markets-work/pprs. Accessed 24 June 2014
Osborne M, Evans TW (1994) Allocation of resources in intensive care: a transatlantic perspective. Lancet 343:778–780
Persson U, Svensson J, Pettersson B (2012) New reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy 10:217–225
Polinder S, Toet H, Pannemen M et al (2011) Methodological approaches for cost-effectiveness and cost-utility analysis of injury prevention measures. The World Health Organisation. http://www.euro.who.int/en/health-topics/disease-prevention/violence-and-injuries/publications/2011/methodological-approaches-for-costeffectiveness-and-costutility-analysis-of-injury-prevention-measures/. Accessed 24 June 2014
Raftery J (2010) Multiple sclerosis risk sharing scheme: a costly failure. BMJ 340:c1672
Raftery J (2012) Moving to value based pricing: adjusting costs. BMJ Group blogs. http://blogs.bmj.com/bmj/2012/11/20/james-raftery-moving-to-value-based-pricing-adjusting-costs/. Accessed 23 June 2014
Raftery J (2013) Value based pricing: can it work? BMJ 347:f5941
Rawlins M (2013) NICE, the first 14 years. Keynote lecture at EACPT Summer School, EACPT, Edinburgh, 5 July 2013
Refoios Camejo R, McGrath C, Herings R et al (2012) Antihypertensive drugs: a perspective on pharmaceutical price erosion and its impact on cost-effectiveness. Value Health 15:381–388
Shah K, Tsuchiya A, Risa Hole A et al (2014) Valuing health at the end of life: an empirical study of public preferences. J Health Econ 15:389–399
SMC (2013) Modifiers used in appraising new medicines. Scottish Medicines Consortium. http://www.scottishmedicines.org/About_SMC/Policy_Statements/SMC_Modifiers_used_in_Appraising_New_Medicines. Accessed 24 June 2013
Sussex (2012) The emerging picture of ‘Value Based Pricing’. Office of Health Economics Kakushen Web based Conference. http://www.slideshare.net/OHENews/emerging-picutre-of-value-based-pricing. Accessed 24 June 2014
Taylor D, Craig T (2009) Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before? Health Econ Policy Law 4:515–526
The Economist (2013) UK/Germany: a question of value. The Economist. http://www.eiu.com/industry/article/41253588/ukgermany-a-question-of-value/2013-11-20. Accessed 24 June 2014
The Health Committee (2008) National Institute for Health and Clinical Excellence: first report of the health committee 2007–2008. House of Commons. Stationery Office, London
Towse A (2010) Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol 70:360–366
Webb DJ (2011) Value-based medicine pricing: NICE work. Lancet 377:1552–1553
Webb DJ, Walker A (2007) Value-based pricing of drugs in the UK. Lancet 369:1415–1416
Whitehead SJ, Ali S (2010) Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 96:5–21
Willis M, Persson U, Zoellner Y et al (2010) Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden. Appl Health Econ Health Policy 8:377–386
Wilsdon T, Fiz E, Haderi A (2014) A comparative analysis of the role and impact of Health Technology Assessment: 2013. PhRMA. http://www.crai.co.uk/ConsultingExpertise/listing.aspx?tID=900&subtID=0&tertID=0&fID=34. Accessed 27 June 2014
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Morrison, E.E., Webb, D.J. (2015). UK Health Technology Assessment and Value Based Pricing. In: Babar, ZUD. (eds) Pharmaceutical Prices in the 21st Century. Adis, Cham. https://doi.org/10.1007/978-3-319-12169-7_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-12169-7_20
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-12168-0
Online ISBN: 978-3-319-12169-7
eBook Packages: Business and EconomicsEconomics and Finance (R0)